atripla

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV InfectionTuberculosisImmunodeficiencyCognition

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

1

Hivid

CConrado Roberto Hoffmann Filho

Phase 3

92

Praluent

Regeneron

Phase 3

13

PEG-Intron

Merck & Co.

Phase 3

—4

Megace

Bristol-Myers Squibb

Phase 3

—5

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

36

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

18

atripla

Gilead

Approved

19

TWINRIX™

GSK

Phase 3

110

Buprenorphine/naloxone

Astellas

Phase 3

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency3 trials

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Completed·Merck & Co.·Phase 3·NCT02403674·734 enrolled

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 2·NCT00869557·71 enrolled

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 3·NCT01095796·707 enrolled

Tenofovir2 trials

PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers

Completed·SSt Stephens Aids Trust·Phase 1·NCT01108926·19 enrolled

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Completed·AAnna Cruceta·Phase 4·NCT01778413·61 enrolled

HIV infection1 trial

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Unknown status·—·Phase 4·NCT01343225·40 enrolled

Pilot Study1 trial

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Withdrawn·CCommunity Research Initiative of New England·Phase 4·NCT01173510

Cognition1 trial

Sleep and Cognition After Atripla to Stribild Switch

Unknown status·UUniversity of Hawaii·Phase 4·NCT02283060·30 enrolled

7 more indications

Double-blind1 trial

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Terminated·UUniversity of Alberta·Phase 4·NCT03532425·28 enrolled

Treatment1 trial

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Completed·UUniversity of California, San Diego·Phase 2·NCT00752856·51 enrolled

Cholesterol1 trial

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Completed·Gilead·Phase 4·NCT00615810·159 enrolled

Tuberculosis1 trial

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 4·NCT01380080·851 enrolled

Interaction1 trial

Interaction With HIV Antiretroviral Agents

Completed·Bayer·Phase 1·NCT02556268·40 enrolled

First-line1 trial

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Completed·PProfessor Francois Venter·Phase 3·NCT03122262·1,110 enrolled

Trial1 trial

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Completed·GSK·Phase 3·NCT01263015·844 enrolled

Details

Drug Info

Related News